ArticleFrontiers in oncology2025
CT radiomics based model for differentiating malignant and benign small (≤20mm) solid pulmonary nodules.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and validation of a radiomics-habitat model for preoperatively predicting poorly differentiated stage IA lung adenocarcinoma.Journal of thoracic disease · 2026Article
- Comparison of clinical-radiological and radiomics features for predicting pulmonary nodule malignancy in a multicenter study of mixed clinical and surveillance populations.European radiology · 2026Article
- The role of radiological imaging in differentiating malignant and benign pulmonary nodules: a retrospective study.BMC medical imaging · 2026Article
- A novel composite model for distinguishing benign and malignant pulmonary nodules.Clinical and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, the computed tomography (CT) radiomics-based models, which can evaluate small (≤ 20 mm) solid pulmonary nodules (SPNs) are lacking. This study aimed to develop a CT radiomics-based model that can differentiate between benign and malignant small SPNs. Methods: This study included patients with small SPNs between January 2019 and November 2021. The participants were then randomly categorized into training and testing cohorts with an 8:2 ratio. CT images of all the patients were analyzed to extract radiomics features. Furthermore, a radiomics scoring model was developed based on the features selected in the training group via univariate and multivariate logistic regression analyses. The testing cohort was then used to validate the developed predictive model. Results: This study included 210 patients, 168 in the training and 42 in the testing cohorts. Radiomics scores were ultimately calculated based on 9 selected CT radiomics features. Furthermore, traditional CT and clinical risk factors associated with SPNs included lobulation (P < 0.001), spiculation (P < 0.001), and a larger diameter (P < 0.001). The developed CT radiomics scoring model comprised of the following formula: X = -6.773 + 12.0705×radiomics score+2.5313×lobulation (present: 1; no present: 0)+3.1761×spiculation (present: 1; no present: 0)+0.3253×diameter. The area under the curve (AUC) values of the CT radiomics-based model, CT radiomics score, and clinicoradiological score were 0.957, 0.945, and 0.853, respectively, in the training cohort, while that of the testing cohort were 0.943, 0.916, and 0.816, respectively. Conclusions: The CT radiomics-based model designed in the present study offers valuable diagnostic accuracy in distinguishing benign and malignant SPNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.